| 前收市價 | 52.82 |
| 開市 | 54.78 |
| 買盤 | 52.06 x 無 |
| 賣出價 | 53.22 x 無 |
| 今日波幅 | 54.36 - 54.78 |
| 52 週波幅 | 47.41 - 60.92 |
| 成交量 | |
| 平均成交量 | 12 |
| 市值 | 無 |
| Beta 值 (5 年，每月) | 0.69 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | 無 |
| 業績公佈日 | 2024年7月30日 - 2024年8月05日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
ZacksIncyte (INCY) Posts Positive Results on Opzelura From HS Study
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
InvestorPlace3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
The global oncology ecosystem is at a pivotal juncture. Significant advancements in discovery, development, and delivery of novel cancer treatments are enhancing patient outcomes. The IQVIA Institute’s report addressed the productivity of clinical development and efforts to improve racial and ethnic representation in clinical trials. Despite advancements, the ecosystem faces challenges, like disparities in patient access to novel cancer medicines across different regions. Moreover, the financial
InvestorPlace7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet. To mitigate the downside risks, it may be better to consider undervalued enterprises. Of course, specifically targeting biotech stocks that trade below their intrinsic or perceived value offers no guarantee of success. Still, given the sometimes extreme mobility that the ecosystem facilitates, it may pa
